IBR-900

N/A

Report date: 2024/11/13 14:54:34

Base Information

Drug NameIBR-900
Drug Alias NameIBR-900
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImbioray (Hangzhou) Biomedicine Co Ltd
Inactive CompaniesBeijing Gao Boren Hospital Co Ltd
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsSolid tumoursLymphoma

Other Information

ATC CodeN/A
Related LinksN/A